C242T polymorphism of the NADPH oxidase p22PHOX gene and its association with endothelial dysfunction in asymptomatic individuals with essential systemic hypertension

Molecular Medicine Reports

Volumn 9, Issue 5, 2014, Pages 1857-1862

  Rafiq, Adnan ^a   Aslam, Khursheed ^b   Malik, Rouf ^b   Afroze, Dil ^b  

^a ASCOMS and Hospital   (India)

^b SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Hypertension; Kashmir; p22PHOX; Polymorphism

Indexed keywords

CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; P22PHOX PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; URIC ACID;

ADULT; AGED; ALLELE; ARTICLE; BLOOD FLOW; BLOOD PRESSURE MEASUREMENT; BRACHIAL ARTERY; C242T GENE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DNA POLYMORPHISM; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ESSENTIAL HYPERTENSION; FEMALE; FRAMINGHAM RISK SCORE; GENE; GENOTYPE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPEREMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; SMOKING; URIC ACID BLOOD LEVEL;

ADULT; ALLELES; ASYMPTOMATIC DISEASES; BRACHIAL ARTERY; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NADPH OXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 84899504808     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.1992     Document Type: Article

References (50)

1. Zeiher AM, Drexler H, Wollschlager H, et al: Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 84: 1984-1992, 1991.
2. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
3. Davignon J and Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation 109: 27-32, 2004.
4. Landmesser U, Horni B and Drexler H: Endothelial function. A critical determinant in atherosclerosis? Circulation 19: 27-33, 2004.
5. Ross R: Atherosclerosis - an inflammation disease. N Engl J Med 340: 115-125, 1999.
6. Altman R: Risk factors in coronary atherosclerosis athero-inflammation: the meeting point. Thrombosis J 1: 4-10, 2003.
7. Schächinger V and Zeiher AM: Atherogenesis - recent insights into basic mechanisms and their clinical impact. Nephrol Dial Transplant 17: 2055-2064, 2002.
8. Ohara Y, Peterson TE, Sayegh HS, et al: Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation 92: 898-903, 1995.
9. Harrison DG: Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100: 2153-2157, 1997.
10. Brandes RP, Barton M, Philippens KM, et al: Endothelial-derived superoxide anions in pig coronary arteries: evidence from lucigenin chemiluminescence and historical techniques. J Physiol 500: 331-342, 1997. (Pubitemid 27193070)
11. Warnholtz A, Nickenig G, Schulz E, et al: Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the rennin-angiotensin system. Circulation 99: 2027-2033, 1999. (Pubitemid 29183901)
12. Rajagopalan S, Kurz S, Münzel T, et al: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 97: 1916-1923, 1996.
13. Guzik TJ, West NEJ, Black E, et al: Vascular superoxide production by NAD(P)H oxidase association with endothelial dysfunction and clinical risk factors. Circ Res 86: 85-90, 2000.
14. Rueckschloss U, Galle J, Holtz J, et al: Induction of NAD(P) oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 104: 1767-1772, 2001. (Pubitemid 32963340)
15. Sumimoto H, Hata K, Mizuki K, et al: Assembly and activation of the phagocyte NADPH oxidase. Specific interaction of the N-terminal Src homology 3 domain of p47PHOX with p22PHOX is required for activation of the NADPH oxidase. J Biol Chem 271: 22152-22158, 1996. (Pubitemid 26303847)
16. Ushio-Fukai M, Zafari AM, Fukai T, et al: p22PHOX is a critical component of the superoxide generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271: 23317-23321, 1996. (Pubitemid 26314775)
17. 2 for platelet derived growth factor signal transduction. Science 270: 296-299, 1995.
18. Zalba G, Jose GS, Moreno MU, et al: NADPH oxidase mediated oxidative stress: genetic studies of p22PHOXgene in hypertension. Antioxid Redox Signal 7: 1327-1336, 2005. (Pubitemid 41232530)
19. Wyche KE, Wang SS, Griendling KK, et al: C242T CYBA polymorphism of NADPH oxidase is associated with reduced respiratory burst in human neutrophils. Hypertension 43: 1246-1251, 2004. (Pubitemid 38696914)
20. Guzik TJ, West NE, Black DE, et al: Functional effects of the C242T polymorphism in the NAD(P)H oxidase p22PHOX gene on vascular superoxide production in atherosclerosis. Circulation 102: 1744-1747, 2000.
21. Laursen JB, Rajagopalan S, Galis Z, et al: Role of superoxide in angiotensin II induced but not catecholamine induced hypertension. Circulation 95: 588-593, 1997. (Pubitemid 27063033)
22. Mollnau H, Wendt M, Szocs K, et al: Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMPsignaling. Circ Res 90: 58-65, 2002.
23. Fukui T, Ishizaka N, Rajagopalan S, et al: p22PHOX mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80: 45-51, 1997. (Pubitemid 27030367)
24. Paravincini TM and Touyz RM: Redox signaling in hypertension. Cardiovasc Res 71: 247-258, 2006.
25. Suzuki H, Swei A, Zweifach BW, et al: In vivo evidence for microvascular oxidative stress in spontaneously hypertensive rats: hydroethidinemicrofluorography. Hypertension 25: 1083-1089, 1995.
26. Nakazono K, Watanabe N, Matsuno K, et al: Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 88: 10045-10085, 1991.
27. Higashi Y, Sasaki S, Nakagawa K, et al: Endothelial function and oxidative stress by products in human hypertension. Hypertension 41: 1096-1101, 2003.
28. Redon J, Oliva MR, Tormos C, et al: Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 41: 1091-1101, 2003.
29. Li L, Fink GD, Watts SW, et al: Endothelin I increases vascular superoxide via endothelin (A)-NAD(P)H oxidase pathway in low rennin hypertension. Circulation 107: 1053-1058, 2003. (Pubitemid 36258731)
30. Beswick RA, Dorrance AM, Leite R, et al: NADH/NADPH oxidase and enhanced superoxide production in the mineralo-corticoid hypertensive rat. Hypertension 38: 1107-1111, 2001. (Pubitemid 34252814)
31. Pettit AI, Wong RK, Lee V, et al: Increased free radical production in hypertension due to increased expression of NADPH oxidase subunit p22PHOX in lymphoblast cell lines. J Hypertens 20: 677-683, 2002. (Pubitemid 34913711)
32. Fortuno A, Olivan S, Beloqui O, et al: Association of increased phagocytic NAD(P)H oxidase dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens 22: 2169-2175, 2004. (Pubitemid 39463811)
33. Zalba G, Beaumont FJ, San Jose G, et al: Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 35: 1055-1061, 2000. (Pubitemid 30327257)
34. Castejon AM, Bracero J, Hoffman IS, et al: NAD(P)H oxidase p22PHOXgene C242T polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics. J Hum Hypertens 20: 772-779, 2006. (Pubitemid 44430676)
35. Nasti S, Balbi M, Fabbi P, et al: CYBA polymorphism associated with oxidative stress in Italian patients with early onset of coronary artery disease. Ital Heart J 3: S52-S54, 2002.
36. Moreno MU, Jose GS, Fortuno A, et al: The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. J Hypertens 24: 1299-1306, 2006. (Pubitemid 43948329)
37. Inoue N, Kawashima S, Kanazawa K, et al: Polymorphism of the NADH/NADPH oxidase p22PHOX gene in patients with coronary artery disease. Circulation 97: 135-137, 1998. (Pubitemid 28124668)
38. Fan M, Kähönen M, Rontu R, et al: The p22PHOX C242T gene polymorphism is associated with a reduced risk of angiographically verified coronary artery disease in a high-risk Finnish Caucasian population. The Finnish cardiovascular study. Am Heart J 152: 538-542, 2006.
39. Shimo-Nakanishi Y, Hasebe T, Suzuki A, et al: Functional effects of NAD(P)H oxidase p22PHOX C242T mutation in human leukocytes and association with thrombotic cerebral infraction. Atherosclerosis 175: 109-115, 2004. (Pubitemid 38746917)
40. Ito D, Murata M, Watanabe K, et al: C242T polymorphism of NADPH oxidase p22PHOX gene and ischemic cerebrovascular disease in the Japanese population. Stroke 31: 936-939, 2000. (Pubitemid 30198442)
41. Cai H, Duarte N, Wilcken DE, et al: NADH/NADPH oxidase p22PHOX C242T polymorphism and coronary artery disease in the Australian population. Eur J Clin Invest 29: 744-748, 1999. (Pubitemid 29425515)
42. Cahilly C, Ballantyne CM, Lim DS, et al: A variant of p22PHOX, involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res 86: 391-395, 2000. (Pubitemid 30141757)
43. Hyashi Okano R, Yamasaki Y, Kajimoto Y, et al: Association of NAD(P)H oxidase p22PHOX gene variation with advanced carotid atherosclerosis in Japanese type 2 diabetes. Diabetes Care 26: 458-463, 2003. (Pubitemid 36929073)
44. Nasti S, Spallarossa P, Aitieri P, et al: C242T polymorphism in CYBA gene (p22phox) and risk of coronary artery disease in a population of Caucasian Italians. Dis Markers 22: 167-173, 2006. (Pubitemid 43893795)
45. Schachinger V, Britten MB, Dimmeler S, et al: NADH/NADPH oxidase p22PHOX gene polymorphism is associated with improved coronary endothelial vasodilator function. Eur Heart J 22: 96-101, 2001. (Pubitemid 32622194)
46. Schneider MP, Hilgers KF, Huang Y, et al: The C242T p22PHOX polymorphism and endothelium-dependent vasodilation in patients with hypercholesterolemia. Clin Sci 105: 97-103, 2003. (Pubitemid 36819582)
47. Li A, Prasad A, Mincemoyer R, et al: Relationship of the C242T p22PHOX gene polymorphism to angiographic coronary artery disease and endothelial function. Am J Med Genet 86: 57-61, 1999. (Pubitemid 29387717)
48. Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999. (Pubitemid 29135798)
49. Inoguchi T, Li P, Umeda F, et al: High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NADPH oxidase in cultured vascular cells. Diabetes 49: 1939-1945, 2000.
50. Hink U, Li H, Mollnau H, et al: Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: E14-E22, 2001.